Psioriasis - How to Stop It ?

These guidelines were developed by the Psoriasis Research Group of the French Dermatology Society with the aim of providing up-to-date decision algorithms for the systemic treatment of adult patients with moderate to severe psoriasis. Our algorithms were generated after a rigorous evaluation of existing guidelines for the treatment of psoriasis and publications regarding new systemic treatments, not yet incorporated into existing guidelines. A total of nine existing guidelines and 53 publications relating to new systemic treatments were found to meet our criteria for use in generating algorithms. We have proposed two new algorithms to assess therapeutic responses, both of which incorporate emerging criteria to assess treatment goals. 

These guidelines are intended for all healthcare professionals involved in the management of patients with psoriasis. The initial working group was made up of three dermatologists (FA, AV, MT), without any conflict of interest with the pharmaceutical industry. Relevant articles were selected using two different methods, depending on the therapeutic agent used - † These. The authors contributed equally to this work. ied. The systematic approach to assessing and adapting © 2019 The authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of the European Academy of Dermatology and Venereology. JEADV 2019 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which allows use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. DOI: 10.1111 / jdv.15340 The JEADV guidelines (ADAPTE) 1 method was used for therapeutic agents already included in the existing guidelines, such as cyclosporine, methotrexate, acitretin, phototherapy, necrosis factor inhibitors tumor (TNF) and ustekinumab. Published guidelines for the treatment of psoriasis were assessed using the Appraisal of Guidelines, REsearch and Evaluation II (AGREE II) scale. 2 Guidelines published between January 2012 and July 2017, for which the total score AGREE was greater than or equal to 90 after two independent evaluations, have been taken into account in the development of these guidelines. In order to identify relevant articles on apremilast, secukinumab, and ixekizumab, we searched the MEDLINE database between January 2014 and October 2017 using terms from the Medical Subject Heading (MeSH): "apremilast", "secukinumab", "ixekizumab" and "psoriasis". The articles were all selected according to the GRADE method (Grading of Recommendations, Assessment, Development and Evaluations)

Updated treatment strategy algorithms, incorporating both established and new systemic therapies, have also been generated for the treatment of plaque psoriasis and psoriatic arthritis, along with recommendations for the treatment of particular forms of psoriasis and the treatment of patients with co-morbidities. Received: April 7, 2018; Accepted: October 12, 2018 Conflicts of Interest FA, AV, MT and BG do not declare any conflict of interest regarding the publication of these recommendations.